GlassScriptPhysician profile
Caroline Kiteley Heideman
NPI 1891229100
$3,796.69
in general payments reported to CMS, 2019-2025
51 companies · $1,273 in 2025
The $1,273 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $711 · 2020: $125 · 2023: $385 · 2024: $1,302 · 2025: $1,273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,838 · Education: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,837.67 |
| Education | $122.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $400.82 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Pfizer INC. | $285.83 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $239.60 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $236.40 | 2024-2025 | |
| Allergan, INC. | $203.75 | 2019-2020 | |
| Daiichi Sankyo INC. | $188.58 | 2023-2025 | Enhertu, Injectafer, Datroway |
| Regeneron Healthcare Solutions, INC. | $164.91 | 2023-2025 | Libtayo |
| Astrazeneca Pharmaceuticals LP | $141.69 | 2024-2025 | Imfinzi, Calquence, Lynparza |
| Incyte Corporation | $132.31 | 2023-2025 | Monjuvi, Jakafi, Pemazyre |
| Celgene Corporation | $126.61 | 2024-2025 | Reblozyl, Pomalyst, Pomalyst |
| Janssen Biotech, INC. | $113.93 | 2024-2025 | Darzalex, Balversa, Erleada |
| Glaxosmithkline, LLC. | $109.11 | 2024-2025 | Jemperli, Ojjaara |
| Array Biopharma INC | $91.82 | 2023-2025 | Mektovi, Braftovi, Lorbrena |
| Gilead Sciences, INC. | $91.23 | 2024-2025 | Trodelvy |
| Genzyme Corporation | $74.01 | 2023-2024 |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $73.57 | 2023-2025 | Fruzaqla, Ninlaro |
| Abbvie INC. | $73.50 | 2023-2025 | |
| Aveo Pharmaceuticals, INC. | $72.03 | 2023-2025 | Fotivda |
| Bayer Healthcare Pharmaceuticals INC. | $69.60 | 2023-2025 | |
| Astellas Pharma US INC | $66.15 | 2024-2025 | Xtandi, Padcev |
| Genentech USA, INC. | $56.71 | 2024-2025 | Phesgo, Tecentriq |
| Beigene USA, INC. | $54.99 | 2023-2024 | Brukinsa, Tevimbra |
| Stemline Therapeutics INC. | $50.62 | 2024-2025 | Orserdu |
| Beone Medicines USA, INC. | $50.49 | 2025 | Brukinsa, Tevimbra |
| Eisai INC. | $50.29 | 2023-2024 | |
| Immunocore Limited | $48.59 | 2024-2025 | Kimmtrak |
| Exelixis INC. | $45.48 | 2024-2025 | Cabometyx |
| Deciphera Pharmaceuticals INC. | $38.32 | 2024 | Qinlock, Tgct |
| Seagen INC. | $31.83 | 2023 | Adcetris, Padcev |
| Amgen INC. | $31.02 | 2019 | |
| Pharmaessentia USA Corporation | $24.58 | 2024 | Besremi |
| Alexion Pharmaceuticals, INC. | $23.86 | 2023 | Ultomiris |
| Pharmacyclics LLC, An Abbvie Company | $22.80 | 2023 | Epkinly |
| Servier Pharmaceuticals LLC | $22.76 | 2024 | |
| Sobi, INC | $21.97 | 2024 | |
| Roche Diagnostics Corporation | $21.83 | 2025 | Inform Her2 Dual Ish Dna Probe Cocktail |
| Sun Pharmaceutical Industries INC. | $21.40 | 2024 | |
| Springworks Therapeutics, INC. | $19.26 | 2025 | Ogsiveo |
| Morphosys, US INC. | $18.93 | 2023 | Monjuvi |
| Acrotech Biopharma INC. | $18.34 | 2024 | Beleodaq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.08 | 2019 | |
| Lilly USA, LLC | $17.75 | 2024 | Retevmo, Jaypirca, Verzenio |
| Sumitomo Pharma America, INC. | $17.26 | 2024 | Orgovyx |
| Kite Pharma, INC. | $16.47 | 2025 | Yescarta |
| Recordati_rare_diseases_inc. | $15.62 | 2024 | Sylvant |
| Geron Corporation | $14.60 | 2025 | Rytelo |
| Mirati Therapeutics, INC. | $13.87 | 2024 | Krazati |
| Agios Pharmaceuticals, INC. | $13.84 | 2025 | Pyrukynd |
| Spectrum Pharmaceuticals INC. | $13.83 | 2024 | Rolvedon |
| Actelion Pharmaceuticals US, INC. | $13.26 | 2019 | |
| Boston Scientific Corporation | $12.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Heideman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.